Immix Biopharma appointed Richard Graydon as Chief Medical Officer in March 2026, but he was terminated in July after it was revealed he was actually Ronald L. Fischer, a fugitive wanted since 2005 for rape charges. This revelation led to a 14.15% drop in Immix's stock price. Pomerantz LLP is investigating whether the company and its officers engaged in securities fraud or other unlawful practices. Investors affected are encouraged to contact the law firm for potential class action participation.
Pomerantz LLP is investigating Karyopharm Therapeutics for potential securities fraud related to a retention program granting top executives lump sum cash bonuses between $625,000 and $1,725,000. The announcement led to a 21.45% drop in Karyopharm's ...
LiveOne announced it will release its first quarter fiscal 2027 financial results on August 12, 2026, with a conference call to discuss the performance. The company expects continued year-over-year growth in revenue and adjusted EBITDA, driven by org...
Robert W. Baird lowered its price target for Fidelity National Information Services (FIS) from $54.00 to $48.00 following the company's mixed Q2 2026 earnings report. FIS posted strong adjusted EPS of $1.48, beating estimates and showing 8.8% growth ...
Uber Technologies continues to lead the U.S. ridesharing market with about 75% share, while expanding its food delivery and advertising businesses. Despite Waymo, Alphabet's self-driving unit, planning to compete directly by launching its own ride-ha...
Fresnillo plc posted its best first-half financial results in 18 years, driven by high precious metals prices and operational efficiency. The company reported earnings per share of $1.75 and revenue of $3.413 billion, both surpassing analyst expectat...
